#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class o...
The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading the race to ...